We are live on ! Find out more
VERV

Verve Therapeutics
VERV

Delisted

VERV was delisted on the 24th of July, 2025.

Back to rankings

69 hedge funds and large institutions have $2.25B invested in Verve Therapeutics in 2021 Q2 according to their latest regulatory filings, with 69 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

81.71% more ownership

Funds ownership: 0% → 81.71% (+82%)

Holders
69
Holders Change
+69
Holders Change %
–
% of All Funds
1.2%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.07%
New
69
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AI
Alphabet Inc
California
+$456M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$165M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$143M
4
CC
Casdin Capital
New York
+$126M
5
RG
Redmile Group
California
+$80.4M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Alyeska Investment Group
26
Alyeska Investment Group
Illinois
$6.03M +$4.15M +100,000 New
EC
27
EcoR1 Capital
California
$6.03M +$4.15M +100,000 New
O
28
OrbiMed
New York
$6.03M +$4.15M +100,000 New
SCM
29
Suvretta Capital Management
New York
$6.03M +$4.15M +100,000 New
Vanguard Group
30
Vanguard Group
Pennsylvania
$3.92M +$2.7M +65,000 New
HF
31
HRT Financial
New York
$3.75M +$2.58M +62,159 New
TA
32
TRB Advisors
New York
$3.62M +$2.49M +60,000 New
PVI
33
Pura Vida Investments
New York
$3.58M +$2.47M +59,393 New
D.E. Shaw & Co
34
D.E. Shaw & Co
New York
$3.48M +$2.4M +57,819 New
Balyasny Asset Management
35
Balyasny Asset Management
Illinois
$2.88M +$1.98M +47,749 New
EGI
36
EAM Global Investors
California
$2.41M +$1.66M +40,055 New
William Blair & Company
37
William Blair & Company
Illinois
$2.15M +$1.48M +35,600 New
GPP
38
Great Point Partners
Connecticut
$2.11M +$1.45M +35,000 New
PCM
39
Pinz Capital Management
New York
$2.1M +$1.44M +34,800 New
Geode Capital Management
40
Geode Capital Management
Massachusetts
$1.93M +$1.33M +32,102 New
Squarepoint
41
Squarepoint
New York
$1.88M +$1.3M +31,253 New
MCM
42
Moore Capital Management
New York
$1.83M +$1.26M +30,446 New
Susquehanna International Group
43
Susquehanna International Group
Pennsylvania
$1.72M +$1.18M +28,525 New
EI
44
EAM Investors
California
$1.71M +$1.18M +28,413 New
Ameriprise
45
Ameriprise
Minnesota
$1.58M +$1.09M +26,282 New
LP
46
LMR Partners
United Kingdom
$1.51M +$1.04M +25,000 New
UAM
47
UAS Asset Management
New York
$1.51M +$1.04M +25,000 New
ACM
48
Asymmetry Capital Management
California
$1.49M +$1.03M +24,790 New
MWNA
49
Marshall Wace North America
New York
$1.11M +$766K +18,451 New
CCM
50
CAAS Capital Management
New York
$904K +$623K +15,000 New
1
2
3

VERV Hedge Fund Activity: Q2 2021 in Review

69 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Verve Therapeutics (VERV) for Q2 2021, worth a combined $2.25B.

Buyers outnumbered sellers: 69 funds opened new VERV positions and 0 closed out — a net gain of 69 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Alphabet Inc, opening a new position worth an estimated $456M.

  • 69 institutional investors held Verve Therapeutics (VERV) as of Q2 2021, up from 0 in Q1 2021.
  • Funds reported $2.25B of Verve Therapeutics stock for Q2 2021.
  • 69 funds opened new Verve Therapeutics positions in Q2 2021 and 0 closed out, a net change of +69 holders.
  • The largest Verve Therapeutics buyer in Q2 2021 was Alphabet Inc, an estimated $456M added.

Based on aggregated 13F filings for Q2 2021.